Vladimir L. Gabai, PhD

Research Assistant Professor, Biochemistry

(617) 638-5970
72 E. Concord St Silvio Conte (K)

Education

  • Moscow State University, PhD

Publications

  • Published on 9/26/2017

    Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, Sherman MY. Correction for Gabai et al., "Heat Shock Transcription Factor Hsf1 Is Involved in Tumor Progression via Regulation of Hypoxia-Inducible Factor 1 and RNA-Binding Protein HuR". Mol Cell Biol. 2017 Oct 15; 37(20). PMID: 28951485.

    Read at: PubMed
  • Published on 8/3/2017

    Halenova T, Savchuk O, Ostapchenko L, Chursov A, Fridlyand N, Komissarov AB, Venanzi F, Kolesnikov SI, Sufianov AA, Sherman MY, Gabai VL, Shneider AM. P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions. Oncotarget. 2017 Aug 22; 8(34):56030-56040. PMID: 28915571.

    Read at: PubMed
  • Published on 3/25/2017

    Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 2017 Mar 25. PMID: 28388548.

    Read at: PubMed
  • Published on 3/25/2017

    Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 2017 Aug 08; 8(32):53730-53739. PMID: 28881846.

    Read at: PubMed
  • Published on 8/8/2016

    Gabai VL, Yaglom JA, Wang Y, Meng L, Shao H, Kim G, Colvin T, Gestwicki J, Sherman MY. Anticancer Effects of Targeting Hsp70 in Tumor Stromal Cells. Cancer Res. 2016 Oct 15; 76(20):5926-5932. PMID: 27503927.

    Read at: PubMed
  • Published on 2/28/2015

    Sabbieti MG, Agas D, Capitani M, Marchetti L, Concetti A, Vullo C, Catone G, Gabai V, Shifrin V, Sherman MY, Shneider A, Venanzi FM. Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent. Oncotarget. 2015 Feb 28; 6(6):3590-9. PMID: 25668818.

    Read at: PubMed
  • Published on 12/30/2014

    Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A, Latanova A, Shcherbinina V, Shifrin V, Shneider A. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget. 2014 Dec 30; 5(24):12803-10. PMID: 25296974.

    Read at: PubMed
  • Published on 10/27/2014

    Sherman MY, Gabai VL. Hsp70 in cancer: back to the future. Oncogene. 2015 Aug 6; 34(32):4153-61. PMID: 25347739.

    Read at: PubMed
  • Published on 10/1/2014

    Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol. 2014 Oct; 33(5):375-82. PMID: 25277339.

    Read at: PubMed
  • Published on 7/3/2014

    Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, Matchuk ON, Smirnova SG, Orlova NV, Zamulaeva IA, Garcia-Marcos M, Li X, Young ZT, Rauch JN, Gestwicki JE, Takayama S, Sherman MY. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res. 2014 Sep 1; 74(17):4731-40. PMID: 24994713.

    Read at: PubMed

View 73 more publications: View full profile at BUMC

View all profiles